Global Cefotaxime Sodium API Sales Market Report 2020
Cefotaxime sodium is the sodium salt form of cefotaxime, a beta-lactam, third-generation cephalosporin antibiotic with bactericidal activity. Cefotaxime sodium binds to and inactivates penicillin-binding proteins (PBP) located on the inner membrane of the bacterial cell wall. Inactivation of PBPs interferes with the cross-linking of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This results in the weakening of the bacterial cell wall and causes cell lysis. Compared to the second and first generation cephalosporins, cefotaxime sodium is more active against gram-negative bacteria and less active against gram-positive bacteria.
Market competition is intense. REYOUNG, Nectar Lifesciences, Medya Pharma, Sandoz, Kelun, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers. Top 5 manufacturers accountted for 57.98% market share in 2019.
Market Analysis and Insights: Global Cefotaxime Sodium API Market
The global Cefotaxime Sodium API market size is projected to reach US$ 97.2 million by 2026, from US$ 102.1 million in 2020, at a CAGR of -0.8% during 2021-2026.
Global Cefotaxime Sodium API Scope and Market Size
The global Cefotaxime Sodium API market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Cefotaxime Sodium API market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2015-2026.
Segment by Type, the Cefotaxime Sodium API market is segmented into
ChP
USP
EP
Chp refers to Chinese Pharmacopoeia. USP refers to the United States Pharmacopeia. EP refers to the European Pharmacopoeia. And the proportion of ChP in 2019 is about 77.92%.
Segment by Application, the Cefotaxime Sodium API market is segmented into
Single Injection
Compound Injection
Cefotaxime sodium API is widely for single injection and compound injection. The proportion of single injection in 2019 is about 76.02%.
The Cefotaxime Sodium API market is analysed and market size information is provided by regions (countries). Segment by Application, the Cefotaxime Sodium API market is segmented into United States, Europe, China, Japan, Southeast Asia, India and Rest of World.
The report includes region-wise market size for the period 2015-2026. It also includes market size and forecast by players, by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Cefotaxime Sodium API market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Cefotaxime Sodium API business, the date to enter into the Cefotaxime Sodium API market, Cefotaxime Sodium API product introduction, recent developments, etc.
The major vendors covered:
REYOUNG
Nectar Lifesciences
Medya Pharma
Sandoz
Kelun
NCPC
Aurobindo Pharma
United Laboratories
Orchid Pharma
CSPC
Kopran
Covalent
ACS Dobfar
Dawnrays
Sterile India
Market competition is intense. REYOUNG, Nectar Lifesciences, Medya Pharma, Sandoz, Kelun, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers. Top 5 manufacturers accountted for 57.98% market share in 2019.
Market Analysis and Insights: Global Cefotaxime Sodium API Market
The global Cefotaxime Sodium API market size is projected to reach US$ 97.2 million by 2026, from US$ 102.1 million in 2020, at a CAGR of -0.8% during 2021-2026.
Global Cefotaxime Sodium API Scope and Market Size
The global Cefotaxime Sodium API market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Cefotaxime Sodium API market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2015-2026.
Segment by Type, the Cefotaxime Sodium API market is segmented into
ChP
USP
EP
Chp refers to Chinese Pharmacopoeia. USP refers to the United States Pharmacopeia. EP refers to the European Pharmacopoeia. And the proportion of ChP in 2019 is about 77.92%.
Segment by Application, the Cefotaxime Sodium API market is segmented into
Single Injection
Compound Injection
Cefotaxime sodium API is widely for single injection and compound injection. The proportion of single injection in 2019 is about 76.02%.
The Cefotaxime Sodium API market is analysed and market size information is provided by regions (countries). Segment by Application, the Cefotaxime Sodium API market is segmented into United States, Europe, China, Japan, Southeast Asia, India and Rest of World.
The report includes region-wise market size for the period 2015-2026. It also includes market size and forecast by players, by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape
and Cefotaxime Sodium API Market Share AnalysisCefotaxime Sodium API market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Cefotaxime Sodium API business, the date to enter into the Cefotaxime Sodium API market, Cefotaxime Sodium API product introduction, recent developments, etc.
The major vendors covered:
REYOUNG
Nectar Lifesciences
Medya Pharma
Sandoz
Kelun
NCPC
Aurobindo Pharma
United Laboratories
Orchid Pharma
CSPC
Kopran
Covalent
ACS Dobfar
Dawnrays
Sterile India
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
Please Select a Format
